Anzeige
Mehr »
Lynx Broker
Login
Montag, 14.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 510300 ISIN: DE0005103006 Ticker-Symbol: ADV 
Xetra
14.10.19
10:35 Uhr
6,310 Euro
-0,020
-0,32 %
1-Jahres-Chart
ADVA OPTICAL NETWORKING SE Chart 1 Jahr
5-Tage-Chart
ADVA OPTICAL NETWORKING SE 5-Tage-Chart
RealtimeGeldBriefZeit
6,300
6,330
11:11
6,310
6,340
11:01
04.02.2019 | 15:08
(55 Leser)
(0 Bewertungen)

MONTREAL, QC / ACCESSWIRE / February 4, 2019 / Sunshine Biopharma Inc. (OTC PINK: "SBFMD"), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer today announced that it has received a "Notice of Allowance" from the United States Patent and Trademark Office for a new patent application covering Adva-27a, the Company's lead anticancer compound. The new patent (US Patent Application Number 20150353573) contains new subject matter and extends the proprietary protection of Adva-27a until 2033. Sunshine Biopharma is the sole owner of all existing intellectual property rights and patents pertaining to Adva-27a, including US Patent Number 8,236,935 issued in 2012.

"We are very excited about this significant development for Adva-27a," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "Allowance of the second Adva-27a patent application gives us 14 years of additional protection and is a validation of the unique and innovative aspects of our anticancer molecule," he added.

Adva-27a is Sunshine Biopharma's proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug's effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are currently being planned to be conducted at the McGill University Hospital Centers in Montreal, Canada.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.



View source version on accesswire.com:
https://www.accesswire.com/534368/Sunshine-Biopharma-Receives-Notice-of-Allowance-for-a-New-Patent-Application-Extending-Protection-of-Adva-27a-Anticancer-Drug-Until-2033


© 2019 ACCESSWIRE